SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
SEC Accession No. 0001628280-18-010933
Filing Date
2018-08-09
Accepted
2018-08-09 16:05:38
Documents
8
Period of Report
2018-06-30

Document Format Files

Seq Description Document Type Size
1 6-K auph-0630186xk.htm 6-K 17949
2 EXHIBIT 99.1 exhibit991-interimconsolid.htm EX-99.1 782314
3 EXHIBIT 99.2 exhibit992-mda06302018.htm EX-99.2 311001
4 EXHIBIT 99.3 exhibit993-certificationof.htm EX-99.3 15870
5 EXHIBIT 99.4 exhibit994-certificationof.htm EX-99.4 15875
6 aurinialogoa02.jpg GRAPHIC 15156
7 q2financialstatementscover.jpg GRAPHIC 70774
8 q2mdacovera01.jpg GRAPHIC 71478
  Complete submission text file 0001628280-18-010933.txt   1355711
Mailing Address #1203-4464 MARKHAM STREET VICTORIA BC A1 V8Z 7X8
Business Address #1203-4464 MARKHAM STREET VICTORIA BC A1 V8Z 7X8 250-708-4272
Aurinia Pharmaceuticals Inc. (Filer) CIK: 0001600620 (see all company filings)

IRS No.: 000000000 | State of Incorp.: A0 | Fiscal Year End: 1231
Type: 6-K | Act: 34 | File No.: 001-36421 | Film No.: 181005014
SIC: 2834 Pharmaceutical Preparations
Assistant Director 1